Phosphorothioate-Conjugated miRNAs for Diverse Industrial Applications
Legal Citation
Summary of the Inventive Concept
Expanding the core technology of phosphorothioate-conjugated miRNAs to address unmet needs in environmental monitoring, agriculture, diagnostics, personalized medicine, and skin health
Background and Problem Solved
The original patent focused on treating diseases, particularly multiple myeloma and IL-6 signaling. However, the technology's potential extends beyond disease treatment. The new inventive concept addresses the limitations of the original patent by exploring novel applications and use cases, unlocking the technology's broader industrial potential
Detailed Description of the Inventive Concept
The new inventive concept leverages phosphorothioate-conjugated miRNAs in various industries. For instance, in environmental monitoring, miRNA sensors can detect specific pollutants. In agriculture, phosphorothioate-conjugated miRNAs can regulate genes involved in plant growth and development, improving crop yields. In diagnostics, miRNA probes can bind to biomarkers of neurological disorders. In personalized medicine, computational platforms can identify optimal miRNA combinations for treating specific diseases. Finally, in skin health, topical administration of phosphorothioate-conjugated miRNAs can regulate genes involved in skin inflammation
Novelty and Inventive Step
The new claims introduce novel applications and use cases that were not originally considered, expanding the technology's scope beyond disease treatment. The inventive step lies in the recognition of the technology's potential in diverse industrial settings and the development of new, non-obvious applications
Alternative Embodiments and Variations
Other potential embodiments include using phosphorothioate-conjugated miRNAs in bioremediation, biotechnology, or cosmetics. Variations may involve different miRNA sequences, conjugation methods, or delivery mechanisms
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in various industries, including environmental monitoring, agriculture, diagnostics, personalized medicine, and skin health. The market size for these industries is substantial, and the technology's adoption could lead to significant revenue growth and societal impact
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/549 |
| A | A61 | A61K47/548 |
| A | A61 | A61K48/00 |
| C | C12 | C12N15/113 |
| C | C12 | C12N2310/141 |
| C | C12 | C12N2320/30 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Molecular biology, biotechnology, and nucleic acid therapeutics, with expertise in microRNA conjugation, delivery mechanisms, and therapeutic applications across multiple domains
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in molecular biology or biotechnology, experienced in nucleic acid design, conjugation techniques, and understanding of miRNA functionality, capable of interdisciplinary problem-solving and technology translation
Obviousness Rationale
A PHOSITA would recognize that phosphorothioate-conjugated miRNAs represent a versatile molecular platform with inherent potential for broad application beyond initial disease treatment. The source patent's fundamental technology of miRNA conjugation provides a clear technological foundation that can be systematically extended to diverse industrial contexts. The disclosed variations represent predictable extrapolations of known molecular engineering principles applied to specific domain challenges.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,633 |
|---|---|
| Title | Phosphorothioate-conjugated miRNAs and methods of using the same |
| Assignee(s) | City of Hope |